The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).
 
Jesse Meir Zaretsky
Stock and Other Ownership Interests - PACT Pharma
 
Dhruv Bansal
Honoraria - MJH Healthcare Holdings, LLC
Research Funding - BostonGene
 
Muhammad Azeem Saeed
No Relationships to Disclose
 
Bo Peng
No Relationships to Disclose
 
Jingqin Luo
No Relationships to Disclose
 
Jessica Klette
No Relationships to Disclose
 
Melissa Andrea Reimers
Honoraria - Society of Urologic Nurses and Associates (SUNA)
Research Funding - Amgen (Inst); BMS GmbH & Co. KG (Inst); FORMA Therapeutics (Inst); Genentech (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst)
 
Russell Kent Pachynski
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Dendreon; EMD Serono; Genomic Health; Jounce Therapeutics; Pfizer/EMD Serono; Sanofi
Speakers' Bureau - AstraZeneca; Dendreon; Genentech/Roche; Genomic Health; Merck; Sanofi
Research Funding - Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Janssen Oncology; Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - Entitled: METHOD OF CELL-FREE DNA ANALYSIS TO IDENTIFY HIGH-RISK METASTATIC PROSTATE CANCER
Travel, Accommodations, Expenses - Genentech/Roche